VentriFlo

Executive Summary

VentriFlo is developing the True Pulse Pump, a novel pulsatile blood pump designed to overcome the limitations of conventional continuous-flow pumps used in cardiopulmonary bypass and ECMO. By mimicking natural cardiac pulsatility, the device may reduce complications such as end-organ dysfunction, hemolysis, and systemic inflammation, potentially improving outcomes for both pediatric and adult patients undergoing cardiac surgery or requiring ICU support. The technology also aims to lower healthcare costs through reduced complications and shorter hospital stays. Based in Minneapolis and founded in 2016, VentriFlo is privately held with limited public information on funding or clinical progress. The company addresses a clear unmet need in a market dominated by decades-old continuous-flow technology, and its pulsatile approach could represent a paradigm shift if clinical data confirm benefits. However, execution risks remain given the early stage and capital-intensive nature of medical device development. With a strong value proposition in cardiopulmonary support, VentriFlo is positioned for potential growth pending regulatory and clinical milestones.

Upcoming Catalysts (preview)

• Q3 2026First-in-human feasibility study results60% success
• Q3 2026FDA breakthrough device designation or 510(k) submission50% success
• Q4 2026Strategic partnership or licensing agreement with a major cardiovascular device company40% success